The brain disease model of addiction: Is it supported by the evidence and has it delivered on its promises?

The Lancet Psychiatry

Volumn 2, Issue 1, 2015, Pages 105-110

  Hall, Wayne ^a,b   Carter, Adrian ^a,c   Forlini, Cynthia ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; BRAIN DISEASE; BRAIN DISEASE MODEL OF ADDICTION; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRINKING BEHAVIOR; GENETICS; HUMAN; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; NOTE; POLICY; SMOKING; ANIMAL; HEALTH CARE POLICY; NATIONAL HEALTH ORGANIZATION; PATHOLOGY; PSYCHOLOGY; SOCIAL STIGMA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

ANIMALS; HEALTH POLICY; HUMANS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); NEUROIMAGING; SOCIAL STIGMA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84920771353     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(14)00126-6     Document Type: Note

References (74)

1. Leshner A Addiction is a brain disease, and it matters. Science 1997, 278:45-47.
2. Dackis C, O'Brien C Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci 2005, 8:1431-1436.
3. Senate Hearing 105-573. Drug addiction and recovery US Government Printing Office, (accessed Sept 26, 2014). http://www.gpo.gov/fdsys/pkg/CHRG-105shrg49670/html/CHRG-105shrg49670.html.
4. Public policy statement: definition of addiction. Chevy Chase, MD American Society of Addiction Medicine, (accessed July 15, 2014). http://www.webcitation.org/62jXWo8dq.
5. Botticelli M National blueprint for drug policy reform released today in Roanoke, VA. Office of National Drug Control Policy media release July 9, 2014 (accessed July 15, 2014). http://www.whitehouse.gov/blog/2014/07/09/national-blueprint-drug-policy-reform-released-today-roanoke-va.
6. Volkow N, Li T Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 2004, 5:963-970.
7. Nature 2014, 506:5. Animal farm.
8. Ahmed S The science of making drug-addicted animals. Neuroscience 2012, 211:107-125.
9. Koob G The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction 2006, 101(suppl 1):23-30.
10. Feltenstein M, See R The neurocircuitry of addiction: an overview. Br J Pharmacol 2008, 154:261-274.
11. Hyman S, Malenka R, Nestler E Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006, 29:565-598.
12. Koob G, Le Moal M Neurobiology of addiction 2006, Academic Press, New York.
13. Panlilio L, Goldberg S Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 2007, 102:1863-1870.
14. Vanderschuren L, Ahmed S Animal studies of addictive behavior. Cold Spring Harb Perspect Med 2013, 3:a011932.
15. Volkow N, Wang G, Fowler J, Tomasi D, Baler R Neuroimaging of addiction. Imaging of the human brain in health and disease 2014, 1-26. Elsevier, San Diego. P. Seeman, B. Madras (Eds.).
16. Volkow N, Fowler J, Wang G, Teland F, Baler R Imaging dopamine's role in drug abuse and addiction. Dopamine handbook 2010, 407-417. Oxford University Press, Oxford. L. Iversen, S. Iversen, S. Dunnett, A. Bjorklund (Eds.).
17. Volkow N, Baler R Addiction science: uncovering neurobiological complexity. Neuropharmacology 2014, 76:235-249.
18. Volkow N, Fowler J, Wang G, Baler R, Telang F Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(suppl 1):3-8.
19. Reske M, Paulus M A neuroscientific approach to addiction: ethical issues. Oxford handbook of neuroethics 2011, 177-202. Oxford University Press, Oxford. J. Illes, B. Sahakian (Eds.).
20. Kendler K, Chen X, Dick D, et al. Recent advances in the genetic epidemiology and molecular genetics of substance use disorders. Nat Neurosci 2012, 15:181-189.
21. Ball D Addiction science and its genetics. Addiction 2008, 103:360-367.
22. Satel S, Lilienfeld S Brainwashed: the seductive appeal of mindless neuroscience 2013, Perseus Books Group, New York.
23. Heyman G Addiction: a disorder of choice 2009, Harvard University Press, Cambridge, MA.
24. Kincaid H, Sullivan J Medical models of addiction. What is addiction? 2010, 353. MIT, Cambridge, MA. D. Ross, H. Kincaid, D. Spurrett, P. Collins (Eds.).
25. Robins L, Helzer J, Hesselbrock M, Wish E Vietnam veterans three years after Vietnam: how our study changed our view of heroin. Am J Addict 2010, 19:203-211.
26. Kleiman M When brute force fails: how to have less crime and less punishment 2009, Princeton University Press, Princeton.
27. Bachman J, Wadsworth K, O'Malley P, Johnston L, Schulenberg J Smoking, drinking, and drug use in young adulthood: the impacts of new freedoms and new responsibilities 1997, Lawrence Erlbaum, Mahwah, NJ.
28. Ahmed S, Lenoir M, Guillem K Neurobiology of addiction versus drug use driven by lack of choice. Curr Opin Neurobiol 2013, 23:581-587.
29. Alexander B, Coambs R, Hadaway P The effect of housing and gender on morphine self-administration in rats. Psychopharmacology (Berl) 1978, 58:175-179.
30. Hall WD, Gartner CE, Carter A The genetics of nicotine addiction liability: ethical and social policy implications. Addiction 2008, 103:350-359.
31. Gartner CE, Barendregt J, Hall WD Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 2009, 104:118-126.
32. Roberts N, Vogelstein J, Parmigiani G, Kinzler K, Vogelstein B, Velculescu V The predictive capacity of personal genome sequencing. Sci Transl Med 2012, 4:133ra58.
33. Button K, Ioannidis J, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013, 14:365-376.
34. Ioannidis J Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 2011, 68:773-780.
35. Ioannidis J, Munafò M, Fusar-Poli P, Nosek B, David S Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. Trends Cogn Sci 2014, 18:235-241.
36. Hall WD, Gartner CE, Mathews R, Munafò M Technical, ethical and social issues in the bioprediction of addiction liability and treatment response. Addiction neuroethics: The ethics of addiction research and treatment 2012, 116-138. Elsevier, New York. A. Carter, W. Hall, J. Illes (Eds.).
37. Lingford-Hughes A, Welch S, Peters L, Nutt D BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012, 26:899-952.
38. Ersche K, Williams G, Robbins T, Bullmore E Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience. Curr Opin Neurobiol 2013, 23:615-624.
39. Hyman S The neurobiology of addiction: implications for the voluntary control of behaviour. Oxford handbook of neuroethics 2011, 203-217. Oxford University Press, Oxford. J. Illes, B. Sahakian (Eds.).
40. Goldstein R, Volkow N Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 2011, 12:652-669.
41. Volkow N, Wang G, Fowler J, Tomasi D Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 2012, 52:321-326.
42. Drugs, brains and behavior: the science of addiction. Washington, DC National Institute on Drug Abuse, (accessed July 15, 2014). http://www.drugabuse.gov/publications/science-addiction.
43. Nutt D, Lingford-Hughes A Addiction: the clinical interface. Br J Pharmacol 2008, 154:397-405.
44. Volkow N, Li T Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther 2005, 108:3-17.
45. Lingford-Hughes A, Watson B, Kalk N, Reid A Neuropharmacology of addiction and how it informs treatment. Br Med Bull 2010, 96:93-110.
46. Kalant H What neurobiology cannot tell us about addiction. Addiction 2010, 105:780-789.
47. Koob G, Lloyd G, Mason B Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nat Rev Drug Discov 2009, 8:500-515.
48. Cahill K, Stead L, Lancaster T Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011, 2. CD006103.
49. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, 9. CD004332.
50. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011, 4. CD001333.
51. Kosten T, Domingo C, Shorter D, et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend 2014, 140:42-47.
52. Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 2012, 8. CD007072.
53. Hall WD, Gartner CE Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Curr Opin Psychiatry 2011, 24:191-196.
54. Paul S, Mytelka D, Dunwiddie C, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9:203-214.
55. Djulbegovic B, Hozo I, Ioannidis J Improving the drug development process: more not less randomized trials. JAMA 2014, 311:355-356.
56. Prinz F, Schlange T, Asadullah K Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov 2011, 10:712.
57. Tsilidis K, Panagiotou O, Sena E, et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 2013, 11:e1001609.
58. Hall WD Stereotactic neurosurgical treatment of addiction: minimising the chances of another 'great and desperate cure'. Addiction 2006, 101:1-3.
59. Luigjes J, van den Brink W, Feenstra M, et al. Deep brain stimulation in addiction: a review of potential brain targets. Mol Psychiatry 2012, 17:572-583.
60. Stephen J, Halpern C, Barrios C, et al. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction 2012, 107:624-634.
61. Rouaud T, Lardeux S, Panayotis N, Paleressompoulle D, Cador M, Baunez C Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation. Proc Natl Acad Sci USA 2010, 107:1196-1200.
62. Carter A, Hall WD Proposals to trial deep brain stimulation to treat addiction are premature. Addiction 2011, 106:235-237.
63. Baltuch G, Stern M Deep brain stimulation for Parkinson's disease 2007, Informa Healthcare, New York.
64. Rose G The strategy of preventive medicine 1992, Oxford University Press, Oxford.
65. Carter A, Hall WD Addiction neuroethics: the promises and perils of neuroscience research on addiction 2012, Cambridge University Press, London.
66. Fiscal Year 2015 Budget information-congressional justification for National Institute on Drug Abuse. Rockville, MD National Institute on Drug Abuse, (accessed July 15, 2014). http://www.drugabuse.gov/about-nida/legislative-activities/budget-information/fiscal-year-2015-budget-information-congressional-justification-national-institute-drug-abuse.
67. White V, Hill D, Siahpush M, Bobevski I How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tob Control 2003, 12:ii67.
68. Pierce J, Gilpin E, Emery S, White M, Rosbrook B, Berry C Has the California tobacco control program reduced smoking?. JAMA 1998, 280:893.
69. Hall WD, Madden P, Lynskey M The genetics of tobacco use: methods, findings and policy implications. Tob Control 2002, 11:119-124.
70. Doran C, Hall WD, Shakeshaft A, Vos T, Cobiac L Alcohol policy reform in Australia: what can we learn from the evidence. Med J Aust 2010, 192:468-470.
71. Miller P, Carter A, De Groot F Investment and vested interests in neuroscience research of addiction: why research ethics requires more than informed consent. Addiction neuroethics: the ethics of addiction research and treatment 2012, 278-301. Elsevier, New York. A. Carter, W. Hall, J. Illes (Eds.).
72. Courtwright D The NIDA brain-disease paradigm: history, resistance, and spinoffs. BioSocieties 2010, 5:137-147.
73. Nutt D, King L, Saulsbury W, Blakemore C Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369:1047-1053.
74. Heim D Addiction: not just brain malfunction. Nature 2014, 507:40.